Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 278

Sort by

Sort Order Select

Journal Articles

A Novel Approach: Nanopore Sequencing of Native Cell-Free DNA in Diffuse-Large B-Cell Lymphoma Patients

Thomas Erblich, Carolin Sauer, Francesc Muyas, Gabriella Ficz, Isidro Cortes-Ciriano, John G. Gribben

Blood (2023) 142 (Supplement 1): 7170.

https://doi.org/10.1182/blood-2023-190154

Published: 2023

Journal Articles

The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia

Carmine Deluca, Michael Beyer, Heather Drew, Jeffrey Murray, Jessica Massey, Brian Koffman, Kristen Battiato, John G. Gribben, Nicole Lamanna, Christina Russomanno

Blood (2023) 142 (Supplement 1): 3715.

https://doi.org/10.1182/blood-2023-177959

Published: 2023

Journal Articles

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Blood (2023) 142 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2023-174891

Published: 2023

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Blood (2023) 142 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2023-182808

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

John G. Gribben, Emmanuel Bachy, Markqayne Ray, Kathryn Krupsky, Kathleen Beusterien, Lewis Kopenhafer, Flor Mendez, Sara Beygi, Timothy Best, Graeme Ball, Kacper Perkowski, Patrick Olsen, Anik R Patel, Paola Ghione

Blood (2023) 142 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2023-190261

Published: 2023

Journal Articles

An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

John G. Gribben, Paola Ghione, Maria Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Olga Nikolajeva, Jiali Yan, Hailin Wang, Anik R Patel

Blood (2023) 142 (Supplement 1): 4869.

https://doi.org/10.1182/blood-2023-186842

Published: 2023

Journal Articles

Allele-Specific Expression of Leukemia Genes Is Associated with Pathogenicity in Poor Risk AML

Blood (2023) 142 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2023-184516

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Targeting the methylome to improve CLL outcome

John G. Gribben

Blood (2023) 142 (1): 4–6.

https://doi.org/10.1182/blood.2023020393

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

John P. Leonard, Marek Trneny, Fritz Offner, Jiri Mayer, Huilai Zhang, Grzegorz S. Nowakowski, Phillip Scheinberg, Argyrios Gkasiamis, Joanna Mikita-Geoffroy, Everton Rowe, John G. Gribben

Blood (2022) 140 (Supplement 1): 561–563.

https://doi.org/10.1182/blood-2022-158631

Published: 2022

Journal Articles

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Lorenzo Falchi, Franck Morschhauser, John G. Gribben, Huiqiang Huang, Minh Dinh, Rebekah Conlon, Xiaorong Chen, Brian Elliot, John F. Seymour

Blood (2022) 140 (Supplement 1): 9338–9339.

https://doi.org/10.1182/blood-2022-157584

Published: 2022

Journal Articles

Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell

Sara Ali, Syed Mian, William Grey, Manuel Garcia-Albornoz, Fatihah Mohamad Nor, Aneesh Sharma, Samantha Atkinson, Linda Ariza McNaughton, John G. Gribben, Dominique Bonnet

Blood (2022) 140 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2022-165316

Published: 2022

Journal Articles

EMT-like Activation in CLL Provides Novel Therapeutic Target

Charlott Repschlaeger, Mariette Odabashian, Filomena Spada, Zamzam Almutairi, John G. Gribben, Francesco Forconi, Emre Sayan, Alexessander Couto Alves, Charline Giroud, Oleg Fedorov, Marina Kriajevskaia, Sergey Krysov

Blood (2022) 140 (Supplement 1): 12375–12376.

https://doi.org/10.1182/blood-2022-162696

Published: 2022

Journal Articles

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Blood (2022) 140 (Supplement 1): 1030–1032.

https://doi.org/10.1182/blood-2022-159069

Published: 2022

Journal Articles

Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation

Megan Perrett, Lucy Pickard, Emil Kumar, Giuseppe Palladino, Faraz Khan, Carina Edmondson, Connor Knight, Edward Poynton, Janet Matthews, Shamzah Araf, Andrew James Clear, Maria Calaminici, John G. Gribben, Hamish King, Mirjana Efremova, Jun Wang, Jessica Okosun

Blood (2022) 140 (Supplement 1): 748–749.

https://doi.org/10.1182/blood-2022-159995

Published: 2022

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer A. Woyach, William G. Wierda, Catherine C. Coombs, Katharine L. Lewis, John G. Gribben, Maricer P. Escalon, Matteo Ceccarelli, Xiaoling Wu, Anthony R. Mato

Blood (2022) 140 (Supplement 1): 12427–12428.

https://doi.org/10.1182/blood-2022-157589

Published: 2022

NARROW

A Novel Approach: Nanopore Sequencing of Native Cell-Free DNA in Diffuse-Large B-Cell Lymphoma Patients

The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

Allele-Specific Expression of Leukemia Genes Is Associated with Pathogenicity in Poor Risk AML

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Targeting the methylome to improve CLL outcome

Genomic profiling for clinical decision making in lymphoid neoplasms

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell

EMT-like Activation in CLL Provides Novel Therapeutic Target

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only